

October 6, 2021

Jack Kong
Chairman
Nano Labs Ltd
30th Floor Dikaiyinzuo
No. 29, East Jiefang Road
Hangzhou, Zhejiang
People's Republic of China

Re: Nano Labs Ltd
Confidential Draft
Submitted September
File No. 377-05474

Registration Statement on Form F-1
9, 2021

Dear Mr. Kong:

We have reviewed your draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments.

Nano Labs Ltd, F-1

Prospectus Cover Page, page i

1. Provide prominent disclosure about legal and operational risks associated with being majority of the company's operations in China. Your disclosure should make clear whether these risks could result in a material change in your operations and/or the value of your ADSs, or could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. Your disclosure should address how regulatory actions by China's government, such as those related to

Jack Kong
FirstName
Nano Labs LastNameJack Kong
Ltd
Comapany
October NameNano Labs Ltd
6, 2021

October
Page 2 6, 2021 Page 2
FirstName LastName

data security or anti-monopoly concerns, has or may impact the company's ability to conduct its business, accept foreign investments, or list on an U.S. or other foreign exchange. Your prospectus summary should address, but not necessarily be limited to, the risks highlighted on the prospectus cover page.

2. Please disclose prominently on the prospectus cover page that you are not a Chinese operating company but a Cayman Islands holding company with operations conducted by your subsidiaries based in China and that this structure involves unique risks to investors. Disclose that investors may never directly hold equity interests in the Chinese operating company. Your disclosure should acknowledge, if true, that Chinese regulatory authorities could disallow this structure, which would likely result in a material change in your operations and/or value of your ADSs, including that it could cause the value of such securities to significantly decline or become worthless. Provide a cross-reference to your detailed discussion of risks facing the company and the offering as a result of this structure.

3. Clearly disclose how you will refer to the holding company and subsidiaries when providing the disclosure throughout the document so that it is clear to investors which entity the disclosure is referencing and which subsidiaries or entities are conducting the business operations. Refrain from using terms such as we or our when describing activities or functions of a subsidiary. Disclose clearly the entity (including the domicile) in which investors are purchasing their interest.
Prospectus Summary, page 1

4. In your summary of risk factors, disclose the risks that your corporate structure and being based in or having the majority of the company's operations in China poses to investors. In particular, describe the significant regulatory, liquidity, and enforcement risks with cross-references to the more detailed discussion of these risks in the prospectus. For example, specifically discuss risks arising from the legal system in China, including risks and uncertainties regarding the enforcement of laws and that rules and regulations in China can change quickly with little advance notice; and the risk that the Chinese government may intervene or influence your operations at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in your operations and/or the value of your ADSs. Acknowledge any risks that any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.

5. Disclose each permission that you or your subsidiaries are required to obtain from Chinese authorities to operate and issue these securities to foreign investors. State whether you or your subsidiaries are covered by permissions requirements from the CSRC, CAC, or any Jack Kong
FirstName
Nano Labs LastNameJack Kong
Ltd
Comapany
October NameNano Labs Ltd
6, 2021
October
Page 3 6, 2021 Page 3
FirstName LastName
other entity that is required to approve of operations, and state affirmatively whether you have received all requisite permissions and whether any permissions

have been denied.

6. Provide a clear description of how cash is transferred through your organization. Disclose your intentions to distribute earnings or settle amounts owed under agreements. Quantify any cash flows and transfers of other assets by type that have occurred between the holding company and its subsidiaries, and direction of transfer. Quantify any dividends or distributions that a subsidiary has made to the holding company and which entity made such transfer, and their tax consequences. Similarly, quantify dividends or distributions made to U.S. investors, the source, and their tax consequences. Describe any restrictions on foreign exchange and your ability to transfer cash between entities, across borders, and to U.S. investors. Describe any restrictions and limitations on your ability to distribute earnings from your business, including subsidiaries, to the parent company and U.S. investors, as well as the ability to settle amounts owed under agreements.

7. Clearly disclose how you will refer to the holding company and subsidiaries when providing the disclosure throughout the document so that it is clear to investors which entity the disclosure is referencing and which subsidiaries or entities are conducting the business operations. Refrain from using terms such as "we" or "our" when describing activities or functions of a VIE. Disclose clearly the entity (including the domicile) in which investors are purchasing their interest.

8. Disclose that trading in your securities may be prohibited under the Holding Foreign Companies Accountable Act if the PCAOB determines that it cannot inspect or fully investigate your auditor, and that as a result an exchange may determine to delist your securities. If the PCAOB has been or is currently unable to inspect your auditor, revise your disclosure to so state.
Risk Factors, page 14

9. In light of recent events indicating greater oversight by the Cyberspace Administration of China over data security, particularly for companies seeking to list on a foreign exchange, please revise your disclosure (page 39-40) to explain how this oversight impacts your business and your offering and to what extent you believe that you are compliant with the regulations or policies that you have been issued by the CAC to date.

10. Given the Chinese government's significant oversight and discretion over the conduct of your business, please revise to separately highlight the risk that the Chinese government may intervene or influence your operations at any time, which could result in a material change in your operations and/or the value of your ADSs. Also, given recent statements by the Chinese government indicating an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, acknowledge the risk that any such action could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of such

Jack Kong

FirstName

Nano Labs LastNameJack Kong
Ltd

Comapany

October NameNano Labs Ltd

6, 2021

October

Page 4 6, 2021 Page 4

securities to significantly decline or be worthless.

ADS Holders may not be entitled to a jury trial, page 57

11. In this risk factor, you say that ADS holders waive the right to a jury trial, including with respect to claims under the federal securities laws. Your disclosure on page 59 indicates and ADS holders and the depository may elect to have any claim settled by arbitration.

Similarly, your disclosure on page 154 indicates that any lawsuit must be brought in state or federal court in New York. Please reconcile.

12. Regarding the waiver of jury trial, arbitration and choice of forum in state or federal court in New York, please revise to state clearly whether each provision applies to claims

arising under the federal securities laws. In that regard, we note that Section 27 of the

Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and

Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts

over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the provision applies to Securities Act claims, please

also revise your prospectus to state that there is uncertainty as to whether a court would

enforce such provision and that investors cannot waive compliance with the federal

securities laws and the rules and regulations thereunder. If this provision does not apply to

actions arising under the Securities Act or Exchange Act, please also ensure that the

exclusive forum provision in the governing documents states this clearly, or tell us how

you will inform investors in future filings that the provision does not apply to any actions

arising under the Securities Act or Exchange Act.

Use of Proceeds, page 63

13. Please revise to describe in more detail the intended use of proceeds referenced in the

second bullet. For example, do you intend to transition from the fables business model

described in this submission? Are the amount of proceeds you intend to devote to this

purpose or will you require additional capital?

Board of Directors, page 124

14. Please revise to state clearly the home country practices on which you intend to rely. In

this regard, we note the disclosure on page 53 that you intend to rely on "some" of those

exemptions. Also, we note the disclosure on the prospectus cover page that you will be a

"controlled company" following this offering. If so, please revise to describe the

exemptions from corporate governance on which you will be entitled to rely and the

related risks to investors.

Transactions with Certain Related Parties, page 128

15. Please revise to clarify the purpose of the borrowings from your affiliates. Please also

update the disclosure in this section to be as of the most recent practicable date.

Jack Kong
Nano Labs Ltd
October 6, 2021
Page 5
General

16. Provide more information on the certifications mentioned on Page 21, and specifically,

whether you paid for the control certifications, or if they were acquired via independent

third party inspection.

17. We note the disclosure that you are a foreign private issuer offering voting securities in the United States. Please tell us how you will determine whether more than 50 percent of its outstanding voting securities are owned of record by U.S. residents for purposes of satisfying the foreign private issuer definition. You may contact Effie Simpson at 202-551-3346 or Jean Yu at 202-551-3305 if you have questions regarding comments on the financial statements and related matters. Please contact Erin Donahue at 202-551-6001 or Geoffrey Kruczek at 202-551-3641 with any other questions.

FirstName LastNameJack Kong

Corporation Finance
Comapany NameNano Labs Ltd

Manufacturing
October 6, 2021 Page 5
cc: Dan Ouyang
FirstName LastName

Sincerely,

Division of

Office of